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After overcoming, in the last century, the obstacle 
of a short life expectancy of about third years, hu-
manity was faced with an amplitude of challenges as-
sociated to the several genetic vulnerabilities linked 
to lifestyle changes and aging. At the center of these 
dis-adjustments, is the type II diabetes mellitus (DM 
II). Despite the persistence of the unbalance in the 
calorie intake and lack of physical activity, according 
to estimates by the International Diabetes Founda-
tion (IDF), the expansion curve for the incidence of 
DM2 shows a slight deceleration, at a ratio of 0.5%. 
However, the condition has already affected 7% of the 
world population of adults and is the cause of around 
10% of all deaths1-8. Thus, a diagnosis of DM2 means 
a decrease of up to two decades in life expectancy, 
according to the type and prematurity of the DM2 
found9. Besides, morbidities such as amaurosis, de-
mentia, neuropathies, and chronic kidney disease 
make this condition a topic of absolute urgency and 
relevancy.
Since it started being recorded, cardiovascular 
disease (CV) has been responsible for 80% of deaths 
of individuals with DM210. Thus, several observation-
al and interventional studies sought to identify the 
primary mediators for CV risk in individuals with 
DM2 in order to improve the risk estimate and inter-
vene slowing down the high mortality. Blood glucose 
control was the most significant intervention for re-
ducing mortality. However, the intensive control of 
blood glucose levels to values close to those of healthy 
individuals did not present any benefits11 and, in one 
of the studies, was even associated with an increase 
in mortality (+2.9 deaths for every 1,000 patients/
year12. Likewise, the control of the arterial pressure 
(-3.2 deaths for every 1,000 patients/year per 10 mm 
Hg)13 and the LDL cholesterol (-2.1 deaths for every 
1,000 patients/year per 39 mg/dL)14 were critical el-
ements in this strategy for risk control. Similarly to 
the blood glucose control, the intensification of these 
interventions did not present any benefits regarding 
survival15,16. In addition, anti-diabetes therapies were 
associated with an increase in the incidence of car-
diovascular diseases17.
The high residual mortality and the uncertainty 
of the CV effects of the therapies led to a demand for 
new treatments systematically tested by cardiovas-
cular safety studies. Despite having been outlined to 
asses safety, two classes of anti-diabetic medication 
have shown a reduction in mortality regardless of 
the effect on glucose: sodium-glucose cotransport-
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er-2 (SGLT-2i) inhibitors (-9 deaths for every 1,000 
patients/year)18 and Glucagon-like peptide-1 (GLP-1) 
agonists (-4 deaths for every 1,000 patients/year)19. 
Thus, over the last five years, not only the reduction 
of the possibility of prolonging the life of DM2 pa-
tients was demonstrated, but it was done as an addi-
tional effect to the control of traditional risk factors.
In this edition, we bring a selection of original 
studies and reviews dedicated to DM2 grouped with 
the purpose of emphasizing the enormous mortality 
of this disease, but also to the substantial advance-
ments achieved for its control.
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